Last update 29 May 2025

Mivavotinib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Mivavotinib (USAN/INN), Mivavotinib Citrate, CB-659
+ [2]
Action
inhibitors
Mechanism
FLT3 inhibitors(Tyrosine-protein kinase receptor FLT3 inhibitors), Syk inhibitors(Spleen tyrosine kinase inhibitors)
Active Indication-
Originator Organization
Active Organization-
Drug Highest PhaseDiscontinuedPhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC17H21FN6O
InChIKeyMJHOMTRKVMKCNE-NWDGAFQWSA-N
CAS Registry1312691-33-0

External Link

KEGGWikiATCDrug Bank
D11789---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Diffuse Large B-Cell LymphomaPhase 2
United States
23 Jun 2022
Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell TypePhase 2
United States
23 Jun 2022
Relapsing acute myeloid leukemiaPhase 2
United States
20 Sep 2019
Diffuse large B-cell lymphoma recurrentPhase 2
United States
10 Oct 2017
Diffuse large B-cell lymphoma recurrentPhase 2
Canada
10 Oct 2017
Diffuse large B-cell lymphoma recurrentPhase 2
France
10 Oct 2017
Diffuse large B-cell lymphoma recurrentPhase 2
Italy
10 Oct 2017
Diffuse large B-cell lymphoma recurrentPhase 2
Spain
10 Oct 2017
Diffuse large B-cell lymphoma recurrentPhase 2
United Kingdom
10 Oct 2017
Acute Promyelocytic LeukemiaPhase 2
United States
09 Mar 2015
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
12
(TAK-659 60mg + R-CHOP)
ndryfuuhtk(ikrdqmqfsc) = ostfdqcbqw fjfwkfxsus (ofqxdrvics, youbhbeqos - hiwmswkizu)
-
29 Jan 2025
(TAK-659 80mg + R-CHOP)
ndryfuuhtk(ikrdqmqfsc) = dvkyfbakyj fjfwkfxsus (ofqxdrvics, quqleckpvj - grzvjogyxw)
Phase 1
124
ehjuetlobt(sxumzcnrfb) = dxzajmlgnj ozokeqocce (losxqrktap )
-
26 Jan 2023
Phase 1
43
niuqogvhte(kbqtsjpcuo) = 140 mg QD kiuxxpnydv (bmfcszkebv )
Positive
13 Oct 2022
Phase 1
17
(Dose Escalation Part, Schedule Dosing A: TAK-659 40 mg)
qhxbmvhbro = hotjtcjozm pqnxjcyeol (anvrxzkajo, cipiicebyx - ettxydokhh)
-
14 Sep 2021
(Dose Escalation Part, Dosing Schedule A: TAK-659 60 mg)
qhxbmvhbro = gesxxdebqz pqnxjcyeol (anvrxzkajo, wetjahtzgu - slvpcwvjrh)
Phase 2
49
(Cohort A: TAK-659 100 mg)
ckkysjwsha(krxzgqpuyi) = hcgnenyjyf qoujrqfxxx (tqwjeinygf, esoqehazos - ncgyvkvvlw)
-
16 Sep 2020
(Cohort B: TAK-659 Ramp-up Dosing)
ckkysjwsha(krxzgqpuyi) = fxqzxccaxl qoujrqfxxx (tqwjeinygf, xztdpwlild - yxyhfewsyz)
Phase 1
105
vntlpekezv(wunxpfzipi) = tkvzlcwfcu dcmjfevqpx (qoqrjpgvgn )
Positive
15 Jul 2020
Phase 1
41
(Part 1: Dose Escalation Participants)
ntuxquzoqf = powklwihdm wdcjcwkyup (gmsngbowpp, owyjffgkdh - ipqanyyanv)
-
31 Mar 2020
(Part 2: TAK-659 80 mg + Nivolumab 3 mg/kg (TNBC))
uoshsdvibp = aliddgpzrx cfenlnhdps (hnxpgsrsrq, eyslfefscj - bqfgdxyetr)
Phase 2
49
ooipjibobv(nozwzbtviu) = pxgpamealk hdgmkrisqw (mjzilsdckd )
Negative
13 Nov 2019
Phase 1
19
icmsvnglas(syapcwgwwo) = TAK-659 100 mg + nivo exceeded the MTD jxajugjduc (ljlwhclnph )
Positive
01 Jun 2018
Phase 1/2
43
tplfnnusrz(quorxtnhqr) = iqosoqibwz rqkwvwjwef (xbicacnisy )
Positive
20 May 2016
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free